Percutaneous Pulmonary Valve Implantation (PPVI) in Australia and New Zealand (ANZ)

Background: The ANZ population undergoing PPVI, including short to medium term outcomes, has not been fully characterised. In particular, there are concerns about infective endocarditis (IE) risk.

Source: Heart, Lung and Circulation - June 23, 2019 Category: Cardiology Authors: C. Lawley, D. Tanous, B. Anderson, D. Celermajer, W. Wilson, S. Shipton, C. O ’Donnell, P. Roberts Tags: 506 Source Type: research